Daiichi Sankyo Korea and AstraZeneca Korea’s human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) “Enhertu Inj (trastuzumab deruxtecan)” is expected to be approved in Korea soon.

This imminent entry of the first treatment for HER2-low breast cancer in Korea attracting much attention.

According to industry sources on the 24th, the Ministry of Food and Drug Safety recently completed the safety and efficacy review for Enhertu.

With the completion of the safety and efficacy review, the industry analysis is that the drug will be soon approved if no other variables arise.

Enhertu, which has indications for breast and gastric c